Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Organon & Co.
< Previous
1
2
Next >
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
August 20, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Reports Results for the Second Quarter Ended June 30, 2024
August 06, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
July 09, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
May 24, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
May 07, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Announces Proposed $1.0 Billion Senior Notes Offering
May 07, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Reports Results for the First Quarter Ended March 31, 2024
May 02, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
April 08, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
April 08, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
February 20, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 15, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
February 01, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
January 10, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
January 08, 2024
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
December 18, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Reports Results for the Third Quarter Ended September 30, 2023
November 02, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
November 01, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
October 19, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
September 27, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology
September 14, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Bolsters Research & Development Expertise with Two Leadership Appointments
September 05, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Reports Results for the Second Quarter Ended June 30, 2023
August 08, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023
July 17, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
July 01, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
June 27, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health
June 07, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon Reports Results for the First Quarter Ended March 31, 2023
May 04, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
Organon To Report First Quarter and Host Conference Call on May 4, 2023
April 20, 2023
From
Organon & Co.
Via
Business Wire
Tickers
OGN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.